10+ hours of deep-diving presentations from industry leaders with new data and novel strategies to share
Ask your burning questions to an exclusive group of gene therapy vector experts during panel discussions with Novartis, Ultragenyx, ViGeneron, Biogen, and more
3 deep-dive workshops to master capsid and payload engineering with Coave Therapeutics, 4D Molecular Therapeutics, Avista Therapeutics, and more
Connect with the whole vector therapy community through a bespoke, close-knit networking environment
Tackle key challenges including off-target effects, unwanted immunogenicity, high and unrepeatable doses, unsuitable preclinical models, limited payload efficacy and discover the newest innovations for AAV capsids, machine learning platforms and non-AAV vectors which tackle target indications with outstanding efficacy
